SPL 3.06% 9.5¢ starpharma holdings limited

Read out on Dep Docetaxel and part of Dep Cabazitaxel Dep...

  1. 12,848 Posts.
    lightbulb Created with Sketch. 1406
    Read out on Dep Docetaxel and part of Dep Cabazitaxel

    Dep Gemcitabine entering the clinic

    Further expansion of indications in clinic for AZD0466

    Phase 1/2 combination arm of DEP® irinotecan + 5-FU + Leucovorin (‘FOLFIRI’ entering the clinic

    TGA approval for Viraleze in Australia

    New partnership agreement with radiotherapeutics

    Merck beginning first in human clinical trials with ADC's

    FDA NDA update

    Monetising undisclosed former blockbuster drug of Astrazeneca with Starpharma's improved version

    Sacking of Mundipharma and finding a real partner

    Licensing our internal in house Dep drugs



    The above is a realistic list of things that I believe can occur over the next 4-5 months

    Of course there are many other possibilities..........

    Look forward to a very productive quarter
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
9.5¢
Change
-0.003(3.06%)
Mkt cap ! $39.17M
Open High Low Value Volume
10.0¢ 10.0¢ 9.5¢ $12.55K 130.3K

Buyers (Bids)

No. Vol. Price($)
4 586785 9.5¢
 

Sellers (Offers)

Price($) Vol. No.
9.7¢ 56840 1
View Market Depth
Last trade - 16.10pm 23/07/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.